Vermillion’s Aspira Labs Secures Expanded Medi-Cal Coverage for OVA1

Posted on by Drea

March 7, 2017

GenomeWeb – Staff Reporter

Vermillion said yesterday that its Aspira Labs subsidiary has won out-of-state provider status with Medi-Cal, California’s Medicaid program, for its OVA1 ovarian cancer test.

The status gives the company access to more than 12 million Medi-Cal beneficiaries, representing roughly one-third of the covered lives in California, Vermillion said.

“This new status is an expansion to our prior Medi-Cal coverage and is key to reaching the entire Medicaid base, as well as expanding OVA1 access in the state with the largest US population,” Valerie Palmieri, president and CEO of Vermillion, said in a statement.

Read Full Article

This entry was posted in News. Bookmark the permalink.

Comments are closed.

Share This
website by filias + APART